Publications & News

WilmerHale Successfully Represents Fabre-Kramer Pharmaceuticals in Collaboration with GlaxoSmithKline

February 8, 2007

WilmerHale successfully represented its client Fabre-Kramer Pharmaceuticals in its worldwide development and commercialization agreement with GlaxoSmithKline for Fabre-Kramer's gepirone ER product, a 5HT1a agonist expected to be submitted in the first quarter of 2007 for FDA review in the US for major depressive disorder (MDD). Under the terms of the agreement, Fabre-Kramer Pharmaceuticals will receive an upfront cash payment followed by additional development and commercialization milestone payments and double-digit percentage royalty payments on worldwide sales of gepirone ER and follow-on products. In return, GlaxoSmithKline was granted an exclusive, worldwide license to develop, manufacture and commercialize gepirone ER and follow-on products.

The WilmerHale lawyers working on the transaction included David Redlick, Steven Barrett, Allison May and James Czaban.